Poseida Therapeutics, Inc.
PSTXDelisted Jan 8, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001661460
Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in Poseida Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
PSTX is no longer listed, and 13F filings after Q4 2024 list far fewer holders. See Q4 2024
- Institutional holders
- 2
- −112 vs. Q4 2024
- Shares held
- 100.0K
- −53.6M (−99.8%) vs. Q4 2024
- Total value
- $308.0K
- −$514.9M (−99.9%) vs. Q4 2024
- New holders
- 0
- 0 more added
- Sold out
- 112
- 0 more reduced
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PSTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 2 | $308.0K |
| Q4 2024 | 116 | $519.2M |
| Q3 2024 | 96 | $153.4M |
| Q2 2024 | 93 | $154.9M |
| Q1 2024 | 91 | $168.6M |
| Q4 2023 | 91 | $152.4M |
| Q3 2023 | 86 | $107.6M |
| Q2 2023 | 94 | $78.4M |
| Q1 2023 | 102 | $136.0M |
| Q4 2022 | 89 | $227.6M |
| Q3 2022 | 68 | $141.8M |
| Q2 2022 | 56 | $58.1M |
| Q1 2022 | 64 | $108.4M |
| Q4 2021 | 66 | $178.4M |
| Q3 2021 | 65 | $190.7M |
| Q2 2021 | 71 | $279.3M |
| Q1 2021 | 62 | $276.3M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Poseida Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sterling Capital Management LLC | 0 | $0 | 0.00% | −1,592−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −1,327−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −777−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −797−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −425−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −329−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −179−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −75−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −42−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |
| Cigogne Management SA | – | – | – | – | Not filed |